Gilead up on HIV drug review

Gilead Sciences (GILD - News) rose 2.4% as an FDA staff report said its Quad pill looks effective at controlling HIV infection but could spur kidney problems that would need monitoring. The FDA will review the report. Fri. An approval decision is expected by Aug. 27.

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    123.70-2.95-2.33%
    RCOM.BO
    61.100.20+0.33%
    APOLLOTYRE.BO
    21.00-1.25-5.62%
    UNITECH.BO
    59.25-4.10-6.47%
    JAIPRA.BO
    24.600.05+0.20%
    IFCI.BO
  • Price % Gainers
    Price % Gainers
    NamePriceChange% Chg
    67.4053.92+400.00%
    AHMEDGA.BO
    20.303.30+19.41%
    TCFCFINQ.BO
    261.0041.00+18.64%
    HINDCOMPQ.BO
    71.8010.90+17.90%
    MAITHANAL.BO
    69.758.70+14.25%
    GILLANDER.BO
  • Price % Losers
    Price % Losers
    NamePriceChange% Chg
    -10.38-100.00%
    ABIRAFN.BO
    -29.60-100.00%
    ACCURATE.BO
    -15.90-100.00%
    ADIRASA.BO
    -31.25-100.00%
    ADMANUM.BO
    -30.05-100.00%
    ADVANIHO.BO

Latest News

MAJOR STOCKS (A-G)

MAJOR STOCKS (H-N)

MAJOR STOCKS (O-Z)

MARKET COMMENTARY

  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.